InflazomeMonday, 19 November 2018
ByrneWallace advise Inflazome Limited in relation to its €40 million Series B Financing to develop NLRP3 inflammasome inhibitors to clinical proof-of-concept. The financing was led by Forbion, with Longitude Capital and founding investors, Novartis Venture Fund and Fountain Healthcare Partners, also participating in what is understood to be one of the largest European venture capital backed financing rounds in the biotech sector this year.
The ByrneWallace team who advised on this transaction were Colin Sainsbury, Partner and Head of Life Sciences, Catherine Dowling, Senior Associate, Emmet Connolly, Solicitor and Catherine Finn, Trainee Solicitor from the ByrneWallace Corporate Team.
Click here for more information on this transaction and to view Inflazome’s press release.